Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 269

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

Open access
Aldoss, Ibrahim, Yang, Dongyun, Aribi, Ahmed, Ali, Haris, Sandhu, Karamjeet, Al Malki, Monzr M., Mei, Matthew, Salhotra, Amandeep, Khaled, Samer, Nakamura, Ryotaro, Snyder, David, O’Donnell, Margaret, Stein, Anthony S., Forman, Stephen J., Marcucci, Guido, Pullarkat, Vinod·2018·Haematologica

Abstract

Venetoclax (ABT-199) is a selective, oral bioavailable inhibitor of BCL-2 that has activity in a variety of hematologic malignancies. BCL-2 expression is high in leukemia stem cells of acute myeloid leukemia (AML), and BCL-2 inhibitors have the potential to sensitize AML cells to hypomethylating agents (HMA), thereby providing the rationale for combining venetoclax with HMA. In an ongoing phase II trial that enrolled treatment-naïve, older (≥65 years) AML patients deemed ineligible for intensive induction therapy, venetoclax, in combination with either decitabine or 5-azacitidine has shown high overall response rate (76%), and this response rate is significantly higher than what is observed with single agent HMA in this setting. The combination of venetoclax with HMA has not been tested systematically in relapsed/refractory (r/r) AML. In a phase II study (n=32), venetoclax was tested as a single agent in r/r AML and produced a modest complete remission (CR)/CR with incomplete recovery (CRi) rate of 19%. We present here “real world” evidence from our institution for the use of venetoclax in combination with HMA in patients with r/r AML treated outside of a clinical trial. We retrospectively analyzed 33 consecutive adults with r/r AML (who failed at least one prior therapy for AML) and were treated with venetoclax in combination with decitabine or 5-azacitidine at the City of Hope Medical Center, Duarte, CA, USA, between October 2016 and October 2017. The study was approved by the Institutional Review Board of the City of Hope Medical Center. We restricted our analysis to evaluable patients who had completed at least one cycle of the combination therapy and had r/r disease based on the assessment of bone marrow biopsy or persistence of circulating leukemia blasts. Venetoclax was given at a dose of 400 mg daily (200 mg daily if the patient was concurrently on an azole). Decitabine dose was given at 20 mg/m/day and either a 5-day (n=15) or 10-day (n=16) course was administered at the discretion of the treating physician. 5-azacitidine (n=2) was given at the dose of 75 mg/m/day for seven days per cycle. Prior treatment with HMA was not an exclusion criterion. We collected data regarding patients’ clinical characteristics, the number and types of prior therapy, cytogenetics and leukemia mutation profile, clinical characteristics and patients’ outcomes. Genetic risk stratification was based on European LeukemiaNet combined cytogenetic and molecular profile. We also collected data on serious adverse events that required hospitalization or prolonged hospitalization during treatment. Consensus criteria were used to define response. Descriptive and univariate analyses were performed for the baseline characteristics and clinical outcomes. Fisher’s exact test and log-rank test were used to explore the differences in tumor response and survival by characteristics. All tests were two-sided at a significance level of 0.05. Patients' and disease characteristics are shown in Table 1. Median age of patients was 62 years (range 19-81). Sixty-one percent (n=20) of patients had failed HMA therapy previously and 39% (n=13) had had prior allogeneic hematopoietic cell transplantation (HCT). Overall response rate (ORR) was 64% (n=21); 10 (30%) patients achieved CR, 7 (21%) CRi, and 4 (12%) morphological leukemia-free state (MLFS). The best response to therapy was seen after a median of 2 (range 1-3) cycles. Among 15 CR/CRi responders who had minimal residual disease (MRD) evaluated at the time of best response, 8 (53%) were MRD negative by multicolor flow cytometry. Three (14%) of the responders who achieved CR/CRi eventually underwent allogeneic HCT. One patient died in remission at day 96 post HCT due to sepsis, one patient relapsed at day 236, and one patient remains in remission at day 134 at the time of analysis. When analysis was restricted to patients who achieved CR/CRi, there was a trend towards higher response in de novo (61%) and therapy-related (60%) AML compared to secondary AML (0%) (P=0.067). None of the 5 patients with secondary AML who were treated with venetoclax and HMA combination responded, but one patient achieved MLFS. All 3 patients with good risk genetic risk [including 1 patient with mutant NPM1 and normal karyotype (NK), one with NK and CEBPA mutation, and 1 with inversion 16] achieved CR/CRi, while only 64% and 39% of patients, respectively, with intermediateand

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3324/haematol.2018.188094

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 269

Metadata

Authors
Aldoss, I., Yang, D., Aribi, A., Ali, H., Sandhu, K., Al Malki, M. M., Mei, M., Salhotra, A., Khaled, S., Nakamura, R., Snyder, D., O’Donnell, M., Stein, A. S., Forman, S. J., Marcucci, G., & Pullarkat, V.
Venue
Haematologica
Published
2018-03-15
Volume
103
Issue
9
Pages
e404-e407
ISSN
  • 0390-6078 (ISSN-L)
  • 1592-8721
OpenAlex
W2793886497
Cited by
269
References
12
FWCI
17.17
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. https://app.cochat.ai/papers/10.3324/haematol.2018.188094
The paper
Aldoss, I., Yang, D., Aribi, A., Ali, H., Sandhu, K., Al Malki, M. M., Mei, M., Salhotra, A., Khaled, S., Nakamura, R., Snyder, D., O’Donnell, M., Stein, A. S., Forman, S. J., Marcucci, G., & Pullarkat, V. (2018). Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. https://doi.org/10.3324/haematol.2018.188094

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.